New combo shot aims to boost flu protection
NCT ID NCT07300085
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests whether giving a high-dose flu vaccine together with a new long-acting antiviral drug (CD388) is safe and does not weaken the body's immune response. About 100 healthy adults aged 18 to 49 will receive either the vaccine plus CD388 or the vaccine plus a placebo. Researchers will measure antibody levels and watch for side effects to see if the combination works well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
California Clinical Trials Medical Group (CCTMG) managed by Parexel
Glendale, California, 91206, United States
-
Parexel International - EPCU Baltimore
Baltimore, Maryland, 21225, United States
Conditions
Explore the condition pages connected to this study.